Statement: There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 27/41 (65.85%)   Febrile Neutropenia 4/41 (9.76%)   Neutropenia 1/41 (2.44%)   Deep Vein Thrombosis 1/41 (2.44%)   Pulmonary embolism 1/41 (2.44%)   Femoral Artery occlusion 1/41 (2.44%)   Abdominal Pain 2/41 (4.88%)   Constipation 1/41 (2.44%)   Fatigue 2/41 (4.88%)   Headache 1/41 (2.44%)   Nausea 1/41 (2.44%)   Cellulitis 1/41 (2.44%)   Muscular Weakness 1/41 (2.44%)
Secondary_evidence: Adverse Events 1:   Total: 15/31 (48.39%)   Intracardiac Thrombus 1/31 (3.23%)   Diarrhoea 2/31 (6.45%)   Nausea 2/31 (6.45%)   Vomiting 2/31 (6.45%)   Ascites 0/31 (0.00%)   Ileus 1/31 (3.23%)   Small Intestinal Obstruction 1/31 (3.23%)   Multi-Organ Failure 0/31 (0.00%)   Sepsis 1/31 (3.23%)   Weight Decreased 1/31 (3.23%)   Dehydration 2/31 (6.45%)   Hypokalaemia 0/31 (0.00%) Adverse Events 2:   Total: 4/31 (12.90%)   Intracardiac Thrombus 0/31 (0.00%)   Diarrhoea 0/31 (0.00%)   Nausea 0/31 (0.00%)   Vomiting 0/31 (0.00%)   Ascites 1/31 (3.23%)   Ileus 0/31 (0.00%)   Small Intestinal Obstruction 0/31 (0.00%)   Multi-Organ Failure 1/31 (3.23%)   Sepsis 0/31 (0.00%)   Weight Decreased 0/31 (0.00%)   Dehydration 0/31 (0.00%)   Hypokalaemia 1/31 (3.23%)